Participated · Series B · Aug 2026

Higgsfield builds an AI-driven platform for generating and iterating short-form video, emphasizing workflows that let users repeatedly rework clips rather than producing one finished asset. The company publicly launched in 2025 and has grown to more than 15 million users across 240 countries. Its business has shifted toward enterprise marketing customers, which now comprise the majority of revenue after moving from under a quarter earlier in 2025. Higgsfield reported annualised revenue of $500 million, up from roughly $200 million at the end of 2025. The team was founded in 2023 by Alex Mashrabov—who previously sold AI Factory to Snap and led generative AI there—alongside CTO Yerzat Dulat and co-founder Mahi de Silva. Management says future investment will prioritize enterprise product development, security, and scaling compute capacity to meet video-generation demand.

Participated · Seed · Apr 2026

Shapes builds a chat app where AI characters (called “Shapes”) participate alongside humans in shared group conversations, and those AI accounts are clearly labeled and can be created and customized by users. The company was founded in 2022 by Anushk Mittal and Noorie Dhingra and has grown largely via word of mouth to more than 400,000 monthly active users. Users have created roughly three million Shapes, and the app reports thousands of users spending two to four hours per day on the platform. Growth accelerated sixfold since the start of the year according to the company. Shapes positions itself as a next‑generation social chat product aimed at highly engaged online communities and fandoms. With the $8 million seed round, the company plans to accelerate development and fund user acquisition efforts.

Participated · Equity · Jan 2026

Lassen Peak is developing a fully integrated handheld radar system that uses submillimeter-wave Terahertz imaging to identify concealed weapons for law enforcement, military, and private security personnel. The device is designed to replace traditional invasive pat-down searches, aiming to reduce use-of-force incidents and increase trust between officers and the public. The company brings together experts in ultra-high-speed wireless, imaging radar, artificial intelligence, and geo-positioning to create this solution. Its advisory board includes former leaders from the ACLU, LAPD, National Organization of Black Law Enforcement Executives, and other public-safety bodies, underscoring its focus on both safety and civil rights. Proceeds from the current financing will fund completion of the charter product and support initial market introduction. While revenue and user figures have not yet been disclosed, management and investors position the company as a potential category-defining “unicorn.”

Participated · Equity · Dec 2025

Cynch AI is a San Francisco–based tax technology company that applies deterministic, non-hallucinatory artificial intelligence to automate the most time-consuming and error-prone elements of tax reporting. Its platform is designed for tax and accounting firms, helping them streamline compliance tasks while preserving the accuracy and client relationships critical to their business. Led by CEO Nigel Duffy, the company operates across the United States and positions itself as an acquirer of traditional tax practices, onboarding their clients onto its AI platform. Cynch AI’s strategy centers on scaling through acquisitions and rapidly deploying its software across newly added customer bases. The firm recently secured $9 million in external capital, providing fresh resources to fuel this roll-up and technology-deployment model. Although specific revenue or user numbers were not disclosed, the new round underscores investor confidence in the company’s growth prospects.

Participated · Equity · Mar 2025

Proscia provides an enterprise pathology platform, Concentriq, plus a precision medicine AI portfolio and real-world data to accelerate development and use of therapies and diagnostics. The company’s products are used daily by pharmaceutical companies and a global network of diagnostic laboratories. Proscia holds FDA 510(k) clearance and CE‑IVDR certification for its diagnostic software. Led by CEO David West, the company focuses on enabling AI to advance precision medicine and tackle diseases such as cancer. Proscia recently raised $50M, bringing its total funding to $130M, and intends to use the proceeds to grow its customer footprint and advance Concentriq’s AI capabilities. Proscia develops a digital pathology software platform and AI applications that automate tasks such as quality control and tumor identification. Its open platform enables partners, customers, and developers to build and deploy disease-specific AI tools, and the company works with cloud providers like AWS and Azure to scale enterprise deployments. The platform is used by 14 of the top 20 pharmaceutical companies to leverage pathology image data for drug discovery and development. Proscia recently received FDA clearance for its software, which allows it to expand into the U.S. diagnostic market. The company raised a $9 million extension to its Series C, bringing the round to $46 million, and plans to use the funds to accelerate commercial growth and further develop its AI-powered applications. Proscia positions itself to address a global pathologist shortage and rising cancer rates as digital pathology adoption accelerates toward widespread use in the next 5–7 years. Proscia provides the Concentriq® platform, which combines enterprise scalability with a broad portfolio of AI applications for digital and computational pathology. Led by CEO David West and based in Philadelphia, the company serves customers including 10 of the top 20 pharmaceutical companies and the Joint Pathology Center, which selected Concentriq to digitize a tissue repository of over 55 million slides. Proscia raised $37M in a Series C to accelerate adoption of computational pathology and strengthen its market and product leadership. The company plans to use the funds to scale commercial operations and expand its sales, marketing, and support teams. Proscia also intends to grow distribution partnerships following a recent OEM agreement with Siemens Healthineers. These investments are aimed at expanding its AI-driven pathology offerings and commercial footprint. Proscia offers the Concentriq digital pathology platform combined with AI-powered applications to digitize high-resolution tissue biopsy images and unlock new insights for laboratories, health systems, and life sciences companies. The company plans to expand its AI application portfolio (building on its DermAI application), grow its data assets, and accelerate commercial expansion by ramping up global sales, marketing, and support teams. Proscia will also advance its regulatory strategy to pursue FDA clearance, building on its existing CE Mark and MDSAP certification. Since closing a Series A in 2018, Proscia has amassed customers including Johns Hopkins School of Medicine, the Joint Pathology Center, and 10 of the top 20 pharmaceutical companies. JPC selected Concentriq to digitize the world’s largest human tissue repository of over 55 million slides. The company positions its software and AI to transform pathology’s historically analog workflows into data-driven diagnostics to improve patient outcomes and accelerate biomedical research. Proscia offers a cloud-based, modular digital pathology platform used by thousands of pathologists, scientists, histotechnicians, and lab managers at more than 300 clinical and research facilities worldwide. The platform integrates with labs' existing environments and technology ecosystems to enable digital adoption, streamline image-based workflows, and open imaging and analytics revenue streams. Proscia is building AI-enabled, disease-specific modules that sit atop its platform to augment pathologists' evaluations and improve diagnostic efficiency and quality. The company plans to commercialize new clinical AI workflows targeting high-volume, high-impact cancers, with its first module, DermAI™, scheduled for release in December 2018. Proscia positions these technologies to increase access to care, reduce turnaround times and costs, and unlock data from tissue to advance cancer research and diagnosis. The company was founded by a team from Johns Hopkins and the University of Pittsburgh to improve clinical outcomes in the fight against cancer.